IL2 and colitis: In a very recent report, a group of researchers demonstrated that low-dose IL-2 expanded Tregs in the blood and spleen in vivo and attenuated DNBS/TNBS-induced colitis in mice; they recently conducted a phase 1b/2a clinical trial of low-dose IL-2 therapy, investigating its safety and therapeutic efficacy in UC patients with moderate-to-severe disease activity 24.